Compare Align Technology, Inc. (ALGN) vs Morgan Stanley (MS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Align Technology, Inc. vs Morgan Stanley — how do they compare? Align Technology, Inc. trades at $179.45 (market cap $12.86B), while Morgan Stanley trades at $222.53 (market cap $350.60B). The key difference: Morgan Stanley is far larger — about 27.3× Align Technology, Inc.'s market cap, and Morgan Stanley pays a 1.8% dividend while Align Technology, Inc. pays none. Which is the better fit depends on your goals.
| ALGN | MS | |
|---|---|---|
Market Cap | $12.86B | $350.60B |
Sector | Health | Financials |
52-Week High | $207.19 | $227.19 |
52-Week Low | $124.88 | $139.09 |
Enterprise Value | $11.92B | — |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Align Technology (ALGN) trades at $179.45, up 0.72% with a bullish technical outlook from moving averages. The company maintains solid profitability with a 10.5% net margin and has beaten EPS estimates for three consecutive quarters. Recent developments include a new manufacturing facility in India and upcoming Q2 2026 earnings on July 29, 2026.
ALGN offers growth potential with a consensus price target of $218.40, representing 22% upside, supported by 73% analyst buy ratings. Risks include European regulatory scrutiny and North American demand pressures. The stock's valuation at 30x P/E requires sustained earnings growth to justify further gains.
Morgan Stanley (MS) trades at $222.28, up 0.07% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with revenue growth from $57.6B in 2024 to $66.0B in 2025 and net income reaching $16.9B. Recent earnings beats and selection to lead Anthropic's IPO highlight operational strength. Technical indicators show support at $220 and resistance at $224, with RSI suggesting mild overbought conditions.
Outlook remains positive with 53.85% analyst buy ratings and $225.80 consensus price target. Key opportunities include wealth management expansion and AI integration, while risks involve volatile cash flows and rising debt-to-asset ratios. The stock offers potential upside but requires monitoring of financial leverage and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Align Technology, Inc.
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
